Trastuzumab: all 614 studies that test it
Page 6 of 7. Open to participants first (88), then studies with results posted, then the rest; newest registration first within each.
- Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast CancerTerminatedNCT00864175Phase 1/2
- Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast CancerTerminatedNCT00817362Phase 2
- A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid TumorsTerminatedNCT00811993Phase 1
- Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast CancerCompletedNCT00788333Phase 1/2
- A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesActive, not recruitingNCT00781612Phase 2
- Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by SurgeryCompletedNCT00769470Phase 2
- Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN StudyCompletedNCT00768859Phase 2
- Trastuzumab Therapy in Non-Small Cell Lung Cancer PatientsTerminatedNCT00758134Phase 2
- Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)CompletedNCT00736970Phase 2
- Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT00724360Phase 2
- Trastuzumab in Treating Women With HER2-Positive Early Breast CancerStatus unknownNCT00712140Phase 3
- Radiation Therapy to the Head in Preventing Brain Metastases in Women Receiving Trastuzumab and Chemotherapy for Metastatic or Locally Advanced Breast CancerCompletedNCT00639366Phase 3
- Trastuzumab Optimization Trial in Breast CancerStatus unknownNCT00637325Phase 3
- Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast CancerStatus unknownNCT00629278Phase 3
- Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast CancerCompletedNCT00615602Phase 3
- The Synergism Or Long Duration (SOLD) StudyCompletedNCT00593697Phase 3
- Bevacizumab in Multiple Phase I CombinationsCompletedNCT00543504Phase 1
- Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast CancerStatus unknownNCT00533936Phase 2
- Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and TrastuzumabCompletedNCT00532857Phase 2
- A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast CancerStatus unknownNCT00486668Phase 3
- Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer PatientsCompletedNCT00485979Phase 2
- Phase I/II Study of Neoadjuvant Lapatinib in Breast CancerCompletedNCT00450892Phase 1/2
- CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast CancerWithdrawnNCT00434031Phase 2
- T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid TumorsCompletedNCT00433407Not applicable
- VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast CancerStatus unknownNCT00431704Phase 2
- Vinorelbine Plus (+) Trastuzumab vs Docetaxel Plus (+) Trastuzumab as 1 Line Treatment for HER2 Positive (+) Metastatic Breast CancerStatus unknownNCT00430001Phase 3
- Randomized Trial With Trastuzumab Versus Observation in Breast Cancer PatientsCompletedNCT00429247Phase 2
- Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast CancerTerminatedNCT00427427Phase 2
- CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD StudyCompletedNCT00412412Phase 1
- HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast CancerCompletedNCT00401427Phase 2
- Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By SurgeryStatus unknownNCT00398489Phase 2
- BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the BrainWithdrawnNCT00397501Phase 1/2
- Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and ImmunogenicityActive, not recruitingNCT00393783Phase 1
- Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast CancerCompletedNCT00387907Phase 2
- XRP9881 in Combination With Trastuzumab in Metastatic Breast CancerCompletedNCT00386685Phase 2
- Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By SurgeryCompletedNCT00381901Phase 3
- Epirubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab in Treating Women With HER2-Positive Stage III or Stage IV Breast CancerCompletedNCT00379015Phase 2
- Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.CompletedNCT00367471Phase 1
- Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast CancerStatus unknownNCT00367250Phase 1
- A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast CancerCompletedNCT00337649Phase 1/2
- Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast CancerCompletedNCT00303992Phase 2
- Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous TrastuzumabCompletedNCT00301899Phase 2
- Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast CancerCompletedNCT00288002Phase 3
- GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast CancerTerminatedNCT00251433Phase 1
- Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast CancerCompletedNCT00238290Phase 2
- Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast CancerTerminatedNCT00216073Phase 2
- PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast CancerTerminatedNCT00216047Phase 1/2
- Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast CancerCompletedNCT00193089Phase 2
- Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast CancerCompletedNCT00193076Phase 2
- A Trial for HER2 Positive Breast Cancer Patients With Metastatic DiseaseCompletedNCT00191373Phase 2
- Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian CancerTerminatedNCT00189579Phase 2
- Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast CancerTerminatedNCT00171847Phase 4
- Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial CancerCompletedNCT00151034Phase 2
- TBP Study With Capecitabine Plus Minus TrastuzumabCompletedNCT00148876Phase 3
- Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast CancerCompletedNCT00146549Phase 3
- UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast CancerCompletedNCT00146042Phase 2
- Neoadjuvant Therapy With Herceptin and Taxol for Breast CancerCompletedNCT00136539Phase 2
- Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBCCompletedNCT00134680Phase 2
- Neoadjuvant Herceptin in Patients With Breast CancerTerminatedNCT00133796Phase 2
- Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With TrastuzumabTerminatedNCT00130507Phase 2
- Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer PatientsCompletedNCT00129896Phase 1/2
- Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland CancerTerminatedNCT00126607Phase 2
- Trastuzumab and Capecitabine in Treating Women With Metastatic Breast CancerCompletedNCT00107393Phase 2
- Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial SarcomaCompletedNCT00104949Phase 2
- Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast CancerCompletedNCT00103233Phase 3
- Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)CompletedNCT00095706Phase 1/2
- GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/NeuCompletedNCT00085020Phase 1
- Trastuzumab and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic HER2/Neu-Expressing CancerCompletedNCT00084513Phase 1
- Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast CancerCompletedNCT00068757Phase 1
- Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast CancerWithdrawnNCT00057993Phase 2
- Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast CancerWithdrawnNCT00054470Phase 2
- Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast CancerCompletedNCT00047255Phase 3
- Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00042809Phase 1
- Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast CancerTerminatedNCT00039455Phase 1
- Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast CancerCompletedNCT00038402Phase 3
- Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast CancerCompletedNCT00036868Phase 2
- Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast CancerCompletedNCT00031278Phase 1/2
- Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid TumorsCompletedNCT00028535Phase 1
- Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast CancerCompletedNCT00024154Phase 2
- Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic OsteosarcomaCompletedNCT00023998Phase 2
- BMS-214662 Plus Trastuzumab in Treating Patients With Advanced Solid TumorsCompletedNCT00022529Phase 1
- Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2CompletedNCT00019812Phase 2
- Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerCompletedNCT00016367Phase 2
- Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast CancerTerminatedNCT00016276Phase 3
- Chemotherapy Plus Trastuzumab in Treating Patients With Breast CancerCompletedNCT00014430Phase 1
- Trastuzumab and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Women With Locally Advanced Breast CancerCompletedNCT00009997Phase 1
- Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast CancerCompletedNCT00006825Phase 1/2
- Celecoxib and Trastuzumab in Treating Women With Metastatic Breast CancerCompletedNCT00006381Phase 2
- Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast CancerCompletedNCT00006228Phase 2
- Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast CancerWithdrawnNCT00006123Phase 1/2
- Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast CancerCompletedNCT00006108Phase 1/2
- Trastuzumab Plus Docetaxel in Treating Women With Recurrent or Metastatic Breast CancerCompletedNCT00006104Phase 2
- Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial CancerCompletedNCT00006089Phase 2
- Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal CancerTerminatedNCT00006015Phase 2
- Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast CancerCompletedNCT00005970Phase 3
- Gemcitabine, Herceptin and Radiation to Treat Cancer of the PancreasCompletedNCT00005926Phase 2
- Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone TherapyCompletedNCT00005857Phase 2
- Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerCompletedNCT00005842Phase 1
- Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract CancerCompletedNCT00005831Phase 2
- Trastuzumab Plus Paclitaxel in Treating Women With Metastatic Breast Cancer That Overexpresses HER2CompletedNCT00005635Phase 2